Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dyW mouse model of MDC1A
Open Access
- 8 February 2021
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 274-287
- https://doi.org/10.1016/j.omtm.2021.02.004
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 73 references indexed in Scilit:
- Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular DystrophyThe American Journal of Pathology, 2012
- Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junctionDevelopmental Neurobiology, 2011
- Apoptosis inhibitors and mini‐agrin have additive benefits in congenital muscular dystrophy miceEMBO Molecular Medicine, 2011
- Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophyAnnals of Neurology, 2009
- The zebrafishcandyflossmutant implicates extracellular matrix adhesion failure in laminin α2-deficient congenital muscular dystrophyProceedings of the National Academy of Sciences of the United States of America, 2007
- Linker molecules between laminins and dystroglycan ameliorate laminin-α2–deficient muscular dystrophy at all disease stagesThe Journal of cell biology, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophyNature, 2001
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Electron microscopic structure of agrin and mapping of its binding site in laminin-1The EMBO Journal, 1998